{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 4 Hyperbilirubinemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 AST elevation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4 Lipase elevation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 Amylase elevation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 4 Amylase elevation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 4 Typhlitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 Febrile Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 3 Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4 Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 4 Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 3 Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 Elevated creatinine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 Acute kidney injury"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3 Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 Peripheral neuropathy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Toxicity, both frequency and severity, will continue to be measured by monitoring the occurrence of adverse events. Adverse events will be defined as those included in CTCAE v 4.03. AEs that were determined to be at least possibly related to study drug and graded 3, 4, 5 are included here. Grade 1 (mild): the event causes discomfort without disruption of normal daily activities. Grade 2 (moderate): the event causes discomfort that affects normal daily activities. Grade 3 (severe): the event makes the patient unable to perform normal daily activities or significantly affects his/her clinical status. Grade 4 (Life-threatening): the patient was at risk of death at the time of the event. Grade 5 (fatal): the event caused death.","groups":[{"description":"Induction:\n\n* Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks)\n\nConsolidation (optional): Identical to Induction.\n\nMaintenance:\n\n* Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease.\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.","id":"OG000","title":"Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From time of treatment to 30 days post discontinuation (range of cycles attempted from induction +/- consolidation, & maintenance = 1-17 cycles) About 1 year Induction = 4 weeks, consolidation = 4 weeks, 1 maintenance cycle = 3 weeks","title":"Number of Participants With Adverse Events Possibly Related to Study Drug Graded 3, 4, and 5","type":"SECONDARY","unitOfMeasure":"Participants"}